Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

A user discusses post-hair transplant care, using Minoxidil, finasteride, Revillus shampoo, and mintop 10% scalp massage. They seek recommendations for mintop solutions available in India and the US.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

RU58841 pre-mixed solution loses effectiveness after two weeks. Users suggest mixing RU58841 powder with ethanol and PG instead of Minoxidil for better results.

A user experienced increased hair shedding and unchanged DHT levels after taking 0.25mg of finasteride for 47 days, leading them to increase the dose to 0.5mg. Others discussed varying experiences with finasteride, minoxidil, and the importance of measuring scalp DHT.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

Using a combination of low-dose topical finasteride (0.025%) and 0.5% pyrilutamide for hair loss, with a focus on minimizing side effects. The user seeks experiences and results from others who have tried this combination.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

A 26-year-old male is using a combination of clomiphene, minoxidil, tadalafil, bupropion, and lisdexamfetamine to address low testosterone, ED, depression, and focus issues. He seeks input on the safety and efficacy of this regimen, which also includes magnesium, zinc, and fish oil supplements.

The user is using a regimen of topical finasteride (.025% concentration), minoxidil, Nutrafol, and vitamin D to address hair loss. They experienced initial side effects but reported improvement over 11 weeks and are considering increasing the dosage.

A 43-year-old male with advanced hair loss is experimenting with alternative treatments, including red light therapy, microneedling, scalp massages, an oil mix, and ketoconazole shampoo, after previously experiencing side effects from finasteride and minoxidil. He noticed some minor changes with red light therapy but remains skeptical about significant improvement.

A 40-year-old male using microneedling, low-level laser therapy (LLT), and rosemary oil for hair regrowth. No finasteride or minoxidil is used.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

A 23-year-old user shared progress pictures after 5 months of using 1.25 mg finasteride, 2x daily topical minoxidil, weekly derma stamping, and occasional Nizoral and mixed topical for dandruff. They report reduced shedding and seek advice on when to confidently grow out their hair.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

Users discussed using lower doses of finasteride and minoxidil for hair loss. Some experienced side effects like arrhythmia, while others reported slowed hair thinning but not complete prevention.

The user experienced significant hair regrowth in 90 days using 1.25 mg finasteride daily and topical 5% minoxidil once a day, with noticeable thickening of eyebrows and eyelashes. Despite the progress, the user plans a hair transplant due to traction alopecia affecting the hairline.

A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.

User shared a 2-year progress update on hair regrowth using 1mg finasteride and 2.5mg oral minoxidil daily. They switched from topical to oral minoxidil for ease of use and showed significant improvement.

The user is seeking an alternative to DualGen 15 that includes Minoxidil and Retinol but is less sticky and more convenient to use. They find the current product inconvenient due to its stickiness and long wait time before washing.

Mixing topical solutions like Morr F 10% (Minoxidil) and L'Oreal Seryoxyl (Stemoxydine) before application may not reduce their effectiveness. The goal is to apply treatments all at once instead of multiple times a day.

The conversation discusses the safety and cost of 2.5mg Dutasteride, and the potential for increased DHT reduction by combining Dutasteride with topical Finasteride. The original poster is currently using 0.5mg Dutasteride, 1.25mg oral Minoxidil, and a topical treatment, and is considering increasing the dosage to maximize results while avoiding less known treatments like RU58841.

The user is using Dutasteride 0.5 mg, Minoxidil 5%, and Microneedling for almost 5 months to address hair loss. They are considering a hair transplant for the front and crown areas due to thinning and a high hairline.

The user experienced temple recession, shedding, and acne while on 0.5mg dutasteride, 1.25mg finasteride every other day, and 5mg oral minoxidil daily. They are considering switching treatments due to worsening symptoms and are contemplating using a topical anti-androgen like RU58841.

A 35-year-old man used minoxidil 5% and biotin 5000 mcg for six months, resulting in significant hair regrowth. He experienced initial shedding but avoided finasteride due to potential side effects.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

The user is on Finasteride for hair loss, taking 0.5mg daily, and plans to reduce the dose to 0.25mg while making lifestyle changes to lower prolactin, SHGB, and cortisol. They will retest in 90 days to assess progress and are open to advice.